Castration-resistant prostate cancer (CRPC)
Prostate cancer is the most commonly diagnosed cancer in men and occurs in a small gland responsible for producing seminal fluid to nourish and transport sperm. Approximately 11 percent of men will be diagnosed with prostate cancer at some time in their life, and there are currently more than 3 million men living with prostate cancer in the U.S.
Androgen deprivation, which blocks testosterone from stimulating cancer growth, is a standard therapeutic approach for advanced prostate cancer. While many patients initially respond to this type of treatment, nearly all patients eventually progress to castration-resistant prostate cancer (CRPC). Metastatic CRPC refers to cancer that has metastasized beyond the prostate gland and is no longer sensitive to androgen deprivation therapies.
Clinical Trial Description:
This Phase 2 study examines the efficacy, safety, tolerability, and pharmacokinetics (PK) of eFT508 (tomivosertib) in metastatic castration resistant prostate cancer patients who have documented PSA progression on treatment with one of three hormone therapies – abiraterone, enzalutamide or apalutamide and for whom no curative therapy exists. The primary objective of this study is to assess the anti-tumor response to eFT508 (tomivosertib) in mCRPC.